Everolimus is a standard chemotherapy drug used to treat a form of kidney cancer called renal cell carcinoma. However, in many patients, the cancer eventually continues to grow. In this study, researchers are determining the highest dose of an investigational drug called SGN-75 that can be given safely with everolimus in patients with metastatic renal cell carcinoma that is positive for a protein called CD70 (the target of SGN-75).
SGN-75 has two parts: one (an antibody) that attaches to CD70 on the surface of cancer cells (including some kidney cancers), and another (an anticancer drug called monomethyl auristatin F) that kills the cancer. SGN-75 is given intravenously (by vein), while everolimus is taken orally (by mouth).